Chemokines in Homeostasis and Cancers

Saeid Abroun, Ph.D.
Hematology Department, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran

* Corresponding Address: P.O.Box: 14155-111, Hematology Department, School of Medical Sciences, Tarbiat Modares University, Tehran, IR.Iran Email: abroun_s@yahoo.co.uk

Abstract
Received: 29/Jun/2008
Chemokines are a small group of related chemoattractant peptides that play an essential role in the development and homeostatic maintenance of the immune system. They control the recruitment of cells needed for the induction and activation of innate and adaptive immune responses. Stromal cell-derived factor 1 (SDF-1) and its receptor (CXCR4) have role in regulation of trafficking of normal hematopoietic stem cells (HSCs) in their homing/retention in bone marrow, also they control lymphocyte trafficking, angiogenesis, cell adherent or migration. In addition, chemokines and their receptors involved in several auto-immune diseases such as inflammation, HIV. In fact, chemokines are involved directly or indirectly in almost every aspect of tumorigenesis. They mediate survival and metastatic spread of tumors, promote new blood vessel formation (neovascularization). SDF-1/CXCR4 axis for migration, enhanced resistance to apoptosis and an increased capacity for drug resistance. A number of therapeutic strategies have been proposed to target almost every step of the chemokine or chemokine receptor involvement in tumors. Yet, despite occasional success stories, most of them appear to be ineffective or impractical. The strategy would only be effective if it also promoted anti-tumor activity and more study is needed to clear the tumor relapse mechanism.

Keywords: Chemokines, chemokine receptors, SDF-1, CXCR4

Table1: Chemokine classification

<table>
<thead>
<tr>
<th>Alpha beta classification</th>
<th>Classic classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>1) Class α or CXC</td>
<td>1) Class I or XC</td>
</tr>
<tr>
<td>2) Class β or CC</td>
<td>2) Class II or CC</td>
</tr>
<tr>
<td>3) Class γ or XC</td>
<td>3) Class III or CXC</td>
</tr>
<tr>
<td>4) Class δ or CX3C</td>
<td>4) Class IV or CX3C</td>
</tr>
</tbody>
</table>

CXC: Cys- any amino acid- Cys

All chemokines are structurally similar and most of them also have at least four cystein in conserved positions. In human the genes encoding CXC chemokine proteins cluster at chromosome 14q12-21 (except for stromal derived factor [SDF]-1a/ CXC ligand 12 whose gene maps to chromosome 10 and genes encoding CC chemokine proteins cluster at chromosome 17q11.2-12 (except for macrophage inflammatory protein [MIP]-3b whose gene maps to chromosome 9 and MIP-3a which maps to chromosome 2), lymphotactin is a strucyurally related chemokine having only one cystein and its gene located in chromosome 1q23. The CX3C chemokin also called “fractalkine” or “neurotactin”, its gene located at chromosome 16 (3).

Some chemokines have role in homeostatic that are produced and secretet constitutively in discrete microenvironments and they are involved in maintaining the physiological trafficking of immune cells (4). Such chemokines are involved in localization of lymphocytes with antigen in lymphatic organs, immune surveillance, stem cell and lymphocyte trafficking. The simplistic view of chemokines as recruiters of immune cells and regulators of the directional migration (chemotactic) is changing owing to important role they play in the innate and adaptive immune responses (5). Other chemokines are only produced by cells during infection (inducible) or a pro-inflammatory stimulus and prompt the migration of leukocytes to an injured or infected site. This inflammatory chemokines can also active cell to raise an immune response and commence the wound healing process (Table 2). Also they play a crucial role in development, inflammatory, autoimmune diseases, HIV infection, tumor associated angiogenesis as well as tumor progression, migration and recruitment of various subsets of immune cells and even malignant cells (Fig 1) (6-8).
<table>
<thead>
<tr>
<th>Chemokines</th>
<th>-ELR-</th>
<th>H/I</th>
<th>Synonyms</th>
<th>Major target cells showing chemotaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CC chemokines</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCL1</td>
<td>NA</td>
<td>I</td>
<td>1-309, TCA3, P500</td>
<td>monocytes, T cells</td>
</tr>
<tr>
<td>CCL2</td>
<td>NA</td>
<td>I</td>
<td>MCP-1, MCAF (mouse; JE)</td>
<td>monocytes, T cells, basophils, NK cells, progenitors</td>
</tr>
<tr>
<td>CCL3</td>
<td>NA</td>
<td>I</td>
<td>LD78α, LD78β, MIP-1α</td>
<td>monocytes, T cells, NK cells, basophils, eosinophils, dendritic cells, hematopoietic progenitors</td>
</tr>
<tr>
<td>CCL4</td>
<td>NA</td>
<td>I</td>
<td>Act-2, G-26, HC21, H400, MIP-1β, LAG-1, SDFy, MAD-5</td>
<td>monocytes, T cells, dendritic cells, NK cells</td>
</tr>
<tr>
<td>CCL5</td>
<td>NA</td>
<td>I</td>
<td>RANTES</td>
<td>progenitors</td>
</tr>
<tr>
<td>CCL6</td>
<td>NA</td>
<td>I</td>
<td>C10 (mouse), MIP-1 (mouse)</td>
<td>T cells, eosinophils, basophils, NK cells, dendritic cells, macrophages,</td>
</tr>
<tr>
<td>CCL7</td>
<td>NA</td>
<td>I</td>
<td>MCP-3 monocytes,</td>
<td>T cells, eosinophils, basophils, NK cells, dendritic cells</td>
</tr>
<tr>
<td>CCL8</td>
<td>NA</td>
<td>I</td>
<td>MCP-2, H5C4</td>
<td>monocytes, T cells, eosinophils, basophils, NK cells</td>
</tr>
<tr>
<td>CCL9</td>
<td>NA</td>
<td>I</td>
<td>MIP-2 (mouse), MIP-1y (mouse)</td>
<td>T cells</td>
</tr>
<tr>
<td>CCL10</td>
<td>NA</td>
<td>I</td>
<td>CCF18</td>
<td>T cells</td>
</tr>
<tr>
<td>CCL11</td>
<td>NA</td>
<td>I</td>
<td>eotaxin</td>
<td>eosinophils, T cells</td>
</tr>
<tr>
<td>CCL12</td>
<td>NA</td>
<td>I</td>
<td>MCP-5 (mouse)</td>
<td>monocytes, T cells, eosinophils</td>
</tr>
<tr>
<td>CCL13</td>
<td>NA</td>
<td>I</td>
<td>MCP-4, NCC-1, CKβ10</td>
<td>monocytes, T cells, eosinophils</td>
</tr>
<tr>
<td>CCL14</td>
<td>NA</td>
<td>I</td>
<td>HCC-1, NCC-3, NCC-2, CKβ1, MCF</td>
<td>monocytes, hematopoietic progenitors</td>
</tr>
<tr>
<td>CCL15</td>
<td>NA</td>
<td>I</td>
<td>HCC-2, NCC-3, MIP-5, Lax-1, MIP-1</td>
<td>monocytes, T cells, eosinophils</td>
</tr>
<tr>
<td>CCL16</td>
<td>NA</td>
<td>I</td>
<td>NCC-4, IEC, HCC-4, LMC, LCC-1, CKβ12</td>
<td>T cells, neutrophils</td>
</tr>
<tr>
<td>CCL17</td>
<td>NA</td>
<td>H</td>
<td>TABC</td>
<td>T cells</td>
</tr>
<tr>
<td>CCL18</td>
<td>NA</td>
<td>H7</td>
<td>DC-CCK1, PARC, MIP-4, CKβ7, DCC1</td>
<td>naïve T cells</td>
</tr>
<tr>
<td>CCL19</td>
<td>NA</td>
<td>H</td>
<td>ELC, MCP-1β, esoxal-3, CKβ11</td>
<td>T cells, B cells, dendritic cells, activated NK cells</td>
</tr>
<tr>
<td>CCL20</td>
<td>NA</td>
<td>H</td>
<td>MIP-3, LARC, esoxal-1, STβ8, CKβ4</td>
<td>T cells, B cells</td>
</tr>
<tr>
<td>CCL21</td>
<td>NA</td>
<td>H</td>
<td>SLC, 6CKin, esoxal-2, TCA4, CKβ9</td>
<td>T cells, B cells, dendritic cells, activated NK cells, macrophage progenitors</td>
</tr>
<tr>
<td>CCL22</td>
<td>NA</td>
<td>H</td>
<td>MDC, STCP-1, DCβ-CR</td>
<td>T cells, eosinophils</td>
</tr>
<tr>
<td>CCL23</td>
<td>NA</td>
<td>H</td>
<td>MIP-3, MIP-1β, CKβ8</td>
<td>dendritic cells, osteoclasts</td>
</tr>
<tr>
<td>CCL24</td>
<td>NA</td>
<td>I</td>
<td>MIP-2, CKβ6, eotaxin-2</td>
<td>effector Th2 cells</td>
</tr>
<tr>
<td>CCL25</td>
<td>NA</td>
<td>H</td>
<td>TECK, CKX15</td>
<td>memory T cells, B cells, immature thymocytes</td>
</tr>
<tr>
<td>CCL26</td>
<td>NA</td>
<td>I</td>
<td>eotaxin-3, IMAC, MIP-4α, TSC-1</td>
<td>eosinophils, T cells</td>
</tr>
<tr>
<td>CCL27</td>
<td>NA</td>
<td>H</td>
<td>ALP, skinkine, ILC, Elkine, PSEEK, CTAK</td>
<td>CLA+ T cells</td>
</tr>
<tr>
<td>CCL28</td>
<td>NA</td>
<td>H</td>
<td>MEC, CCK1</td>
<td>T cells</td>
</tr>
<tr>
<td><strong>CXC chemokines</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CXCL1</td>
<td>ELR+</td>
<td>I</td>
<td>GROα, MIA-α, NAP-3 (mouse/cat, Kc, MIP-2, CINC-2β)</td>
<td>neutrophils, endothelial cells</td>
</tr>
<tr>
<td>CXCL2</td>
<td>ELR+</td>
<td>I</td>
<td>GROα, MIP-2α, MIA-β, CINC-2α</td>
<td>neutrophils, endothelial cells</td>
</tr>
<tr>
<td>CXCL3</td>
<td>ELR+</td>
<td>I</td>
<td>GROβ, MIP-2β, CINC-2β</td>
<td>neutrophils</td>
</tr>
<tr>
<td>CXCL4</td>
<td>ELR+</td>
<td>I</td>
<td>PF4 fibroblasts</td>
<td>endothelial cells</td>
</tr>
<tr>
<td>CXCL5</td>
<td>ELR+</td>
<td>I</td>
<td>ENA-78</td>
<td>neutrophils</td>
</tr>
<tr>
<td>CXCL6</td>
<td>ELR+</td>
<td>I</td>
<td>GCP-2</td>
<td>neutrophils</td>
</tr>
<tr>
<td>CXCL7</td>
<td>ELR+</td>
<td>I</td>
<td>CTAP-8, NAP-2, LA-PA, MDG, LCG, β-TG</td>
<td>Fibroblasts</td>
</tr>
<tr>
<td>CXCL8</td>
<td>ELR+</td>
<td>I</td>
<td>IL-8, NAP-1</td>
<td>neutrophils, T cells, B cells, endothelial cells</td>
</tr>
<tr>
<td>CXCL9</td>
<td>ELR-</td>
<td>I</td>
<td>Mig</td>
<td>T cells, progenitors</td>
</tr>
<tr>
<td>CXCL10</td>
<td>ELR-</td>
<td>I</td>
<td>IP-10</td>
<td>T cells</td>
</tr>
<tr>
<td>CXCL11</td>
<td>ELR-</td>
<td>I</td>
<td>S-TAC</td>
<td>T cells</td>
</tr>
<tr>
<td>CXCL12</td>
<td>ELR-</td>
<td>I</td>
<td>SDF-1, SDF-1β, PBSF</td>
<td>monocytes, B cells, hematopoietic progenitors, non-hematopoietic cells</td>
</tr>
<tr>
<td>CXCL13</td>
<td>ELR-</td>
<td>H</td>
<td>BLK, BCA-1</td>
<td>B cells</td>
</tr>
<tr>
<td>CXCL14</td>
<td>ELR-</td>
<td>I</td>
<td>BAK, bolekin, MIP-2, BMAC, KS1</td>
<td>neutrophils, NK cells, B cells</td>
</tr>
<tr>
<td>CXCL15</td>
<td>ELR-</td>
<td>H</td>
<td>lungkine</td>
<td>airspace neutrophils</td>
</tr>
<tr>
<td>CXCL16</td>
<td>ELR-</td>
<td>?</td>
<td>SR-PSOX, SEXCKINE</td>
<td>dendritic cells</td>
</tr>
<tr>
<td><strong>C chemokines</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XCL1</td>
<td>NA</td>
<td>I</td>
<td>lymphotactin, SCM-1, ATAC</td>
<td>B cells, T cells, NK cells, neutrophils</td>
</tr>
<tr>
<td>XCL2</td>
<td>NA</td>
<td>I</td>
<td>SCM-1</td>
<td>B cells, T cells, NK cells, neutrophils</td>
</tr>
</tbody>
</table>

*H*, homeostatic chemokine; I, inflammatory chemokine; NA, not applicable. For definitions of the various synonyms (10), ELR, The glutamic acid-leucine-arginine sequence in front of CXC group which promote angiogenesis.
Table 3: Chemokine receptors

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Synonyms</th>
<th>Chemokine ligands</th>
<th>Receptor-expressing cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCR1</td>
<td>CKR1, CC CKR1, CMKBR1</td>
<td>CCL3,5,7,8,13,14,15,16,23</td>
<td>monocytes, immature DCs, T cells, PMNs, eosinophils, esangial cells, platelets</td>
</tr>
<tr>
<td>CCL3, 5, 7, 8, 13, 15, 16, 23</td>
<td>CKR2, CC CKR2, CMKBR2</td>
<td>CCL2,7,8,12,13</td>
<td>monocytes, immature DCs, basophils, PMNs, T cells, NK cells, endothelial cells, fibroblasts</td>
</tr>
<tr>
<td>CCR3</td>
<td>CKR3, CC CKR3, Eot R CMKBR3</td>
<td>CCL5,7,8,11,13,14,15,24,26</td>
<td>eosinophils, basophils, T cells (Th2&gt;Th1), DCs, latelets, mast cells</td>
</tr>
<tr>
<td>CCR4</td>
<td>CKR4, CC CKR4, CMKBR4,K5-5</td>
<td>CCL17,22</td>
<td>immature DCs, basophils, T cells (Th2&gt;Th1), platelets</td>
</tr>
<tr>
<td>CCR5</td>
<td>CKR5, CC CKR5, ChemR1</td>
<td>CCL3,4,5,8,11,13,14,20</td>
<td>Th1 cells, immature DCs, monocytes, NK cells, CMKBR5 hycocytes</td>
</tr>
<tr>
<td>CCR6</td>
<td>GPR-CY4, CKR-L3, STRL22, CRY-6, DCR2, CMKBR6</td>
<td>CCL20</td>
<td>immature DCs, T cells, B cells</td>
</tr>
<tr>
<td>CCR7</td>
<td>BLR-2, CMKBR7</td>
<td>CCL19,21</td>
<td>mature DCs, T cells, B cells</td>
</tr>
<tr>
<td>CCR8</td>
<td>TER1, CKR-L1, GPR-CY6, ChemR1, CMKBR8</td>
<td>CCL1,4,1</td>
<td>monocytes, B cells, T cells, thymocytes</td>
</tr>
<tr>
<td>CCR9</td>
<td>GPR9-6</td>
<td>CCL25</td>
<td>T cells, thymocytes, DCs, macrophages</td>
</tr>
<tr>
<td>CCR10</td>
<td>GPR2</td>
<td>CCL27,28</td>
<td>T cells, melanocytes, dermal endothelia, dermal fibroblasts, Langerhans cells,</td>
</tr>
<tr>
<td>CCR11</td>
<td>PPR1</td>
<td>CCL2,8,13,19,21,25</td>
<td>astrocytes</td>
</tr>
<tr>
<td>CXCR1</td>
<td>IL-8RA, IL-8R-I, IL-8R</td>
<td>CXCL1,2,3,5,6,7,8</td>
<td>PMNs, monocytes, astrocytes, endothelia, mast cells</td>
</tr>
<tr>
<td>CXCR2</td>
<td>IL-8RB, IL-8R-II, IL-8R</td>
<td>CXCL1,2,3,5,6,7,8</td>
<td>PMNs, monocytes, eosinophils, endothelia, mast cells</td>
</tr>
<tr>
<td>CXCR3</td>
<td>IP10/MigR, GPR9</td>
<td>CXCL9,10,11</td>
<td>T cells (Th1-Th2), B cells, NK cells, mesangial cells, smooth muscle cells, endothelia</td>
</tr>
<tr>
<td>CXCR4</td>
<td>HUMSTS fusin, LESTR,HM89</td>
<td>CXCL12</td>
<td>hematopoietic progenitors, T cells, immature DCs, monocytes, B cells, PMNs, platelets, astrocyte, endothelia</td>
</tr>
<tr>
<td>CXCR5</td>
<td>BLR-I, MDR15</td>
<td>CXCL13</td>
<td>T cells, B cells, astrocytes</td>
</tr>
<tr>
<td>CXCR6</td>
<td>Bonzo, STRL33, TYMSTR</td>
<td>CXCL16</td>
<td>memory T cells</td>
</tr>
<tr>
<td>XCR1</td>
<td>GPR5</td>
<td>XCL1, XCL2</td>
<td>T cells</td>
</tr>
<tr>
<td>X3CR1</td>
<td>GPR13, V28, CMKBR1</td>
<td>X3CL1</td>
<td>PMNs, monocytes, NK cells, T cells, astrocytes</td>
</tr>
<tr>
<td>Duffy</td>
<td>DARC</td>
<td>CXCL1,7,8, CCL1,5</td>
<td>red blood cells, endothelia</td>
</tr>
<tr>
<td>D6</td>
<td>CR9,10, JAB61</td>
<td>CCL2,4,5,8,13,14,15</td>
<td>B cells</td>
</tr>
</tbody>
</table>

**Chemokine Receptors**

Chemokines transmit their signaling via binding with cell-surface G protein -coupled seven-transmembrane receptors, so-called chemokine receptors (Fig 2), designated CXCR1-8, CCR1-11, CXCR1 and CX3CR1 (11).

Most of chemokines recognize one or more cell surface receptors and most of receptors have more than one ligand (Table 3). Chemokine receptors share 25-80% homology in 340-370 amino acid residues with an acidic N-terminus, conserved ten amino acid sequence in the second intracellular loop, and one cysteine in each of the four extracellular domains. The chemokin binding site is complex and it located in N-terminal segment (12).

**Major biological function of chemokines and receptors**

Hemostastasis and development
Studies show the important roles for some chemokines in hematopoiesis and organ development. Hematopoiesis is an active progression controlled by a variety of cytokines. It is well clear that the chemokine family plays an critical role in this regulatory system. At least 25 chemokines of the CC, CXC and C subgroups have been found to suppress the in vitro proliferation of myeloid progenitor cells (12, 13). However, the in vivo evidence based on knock-out mice studies provides data of contrasting hematopoietic effect for only few of the chemokines and their receptors. For example, CCL3 (MIP-1α) arrests cell cycling and reduces the bone marrow progenitor cells number in mice (14). Mice depleted of CCR1, as CCL3 receptor, display enhanced lineage-committed myeloproliferation and leukocyte mobilization into the blood stream (15). CXCL12 (SDF-1) is constitutively expressed by stromal cells in bone marrow, promotes proliferation of B cell progenitors (16), and recruit hematopoietic precursors to the bone marrow in embryogenesis time (17). Mice deficient in CXCL12 (SDF-1) or its receptor (CXCR4) die before birth with B lymphopoiesis and myelopoiesis deficiency and also with an incomplete development of the cardiac septums and cerebellum development, it show the involvement of CXCL12/CXCR4 pair in a number of vital developmental processes (18-20). The thymus is organ for T cell development and it expresses mRNA for several chemokines with lymphocyte-attracting properties, that well described (21,22). Some chemokines control the development and organization of secondary lymphoid organs such as peripheral lymph nodes and Peyer’s patches (23,24).

**Fig 1: The role of chemokines and receptors in patho-physiologic conditions**

**Fig 2: Schematics shame of Chemokines receptors which their genes were regularly on chromosomes 14 and 17 in human**

**Leukocyte trafficking and homing**
Chemokines control lymphocyte trafficking in immune system homeostasis., Lymphocyte homing to lymphoid and non-lymphoid tissues and recirculation between secondary lymphoid organs critically depend on the chemokines present in different sites. For example, CCL19 and CCL21 (which bind to CCR7), and CXCL13 (which binds to CXCR5), are expressed in the lymphatic vessels, high endothelial venules (HEVs) and secondary lymphoid organs, to promote the entry of antigen-presenting cells (APCs), T cells and B cells into these organs (25). Immune cell, DC precursors in peripheral tissues phagocytose microorganisms or cell debris and are activated by pathogens or antigens then start to maturation and CCR7expression which enables them to migrate in response to CCR7 ligands into the draining lymph nodes via the lymphatic vessels, and to infiltrate the T-cell zones where they present processed antigen epitopes to T cells (26). In contrast to DCs, B cells and naïve T cells enter lymph nodes through HEVs. The CCR7 ligands CCL19 and CCL21 by the endothelial cells of HEVs are transcytosed to the luminal surface and induce lymphocyte extravasation to the T-cell zones of the lymph nodes (27). CCL19 produced by mature, inter digitating DCs facilitates the “scanning” of DCs by naïve T cells in the lymphoid organs in search of their cognate antigens (26). B cells express CXCR5/CXCL13 is produced by follicular stromal cells in lymph nodes. B cells proliferate in the follicles, giving rise to germinal centers (GC) after activated by T cells. Activated T cells expressing CXCR5 may also enter the follicles to participate in the T-B interaction. In addition, CCL19 and CCL21 are responsible for the proper positioning of lymphocytes within distinct microenvironments of lymphoid organs. For instance, CCL19 and CCL21, expressed by DCs and stromal cells retain T cells within the T-cell zones of secondary lymphoid organs. On the other hand, CXCL13 expressed by follicular DCs and stromal cells in follicles attracts B cells and some of the T cell subsets into the B-cell areas. Furthermore, the capacity of B cells to respond to CCR7 as well as CXCR5 ligands controls the position of B cells at the boundary of the follicles and T-cell zones in the spleen, where naïve, mature B cells interact with T cells that are newly activated in the adjacent zones (28,29). Non-activated B cells and T cells then leave

**Angiogenesis**
Angiogenesis occurs rapidly but transiently and is tightly regulated physiologically, but unbalanced production of CXC subgroup of chemokines which act as positive and negative regulators, results pathological angiogenesis that seen during chronic inflammation and tumor growth. CXC containing ELR motif (10), CXCL8 (IL-8), CXCL5 (ENA78), and CXCL1, 2, 3 (GRO-α, β, γ) induce vessel formation in rabbit cornea (15, 16). In contrast, ELR negative CXC chemokines CXCL4 (PF4), CXCL10 (IP-10) and CXCL9 (MIG) abrogate the angiogenesis induced by ELR+ CXC chemokines (30,31).
One exception is CXCL12 (SDF-1), which despite the absence of the ELR motif, acts as an angiogenic factor both in vitro and in vivo had reported (32). Angiogenesis is crucial for tumor growth. The ELR positive CXC chemokine CXCL8 promotes neovascularization and tumorgenesis of ovarian carcinoma (33). Treatment of the mice bearing CXCL8 producing tumors with anti-CXCL8 antibodies or with angiostatic chemokine CXCL10 (IP-10) inhibits tumor growth and metastasis (34, 35). These results confirm the proposals to utilize selected chemokines or their inhibitors to control angiogenesis in tumor and wound healing.

It should be noted that most of the results regarding the activity of chemokines in angiogenesis and angiostasis had achieved from in vitro or specifically designed experiments in animals. However more information should be reached by using knockout models. In this way, mice missing its SDF-1 or its exclusive receptor show defects in cardiovascular development and provide clear evidence of an important role for this chemokine and receptor in angiogenesis during development.

**Inflammation**

It has known the key role of chemokines in inflammation event. Chemokines participate in and control the process of a number of acute and chronic inflammatory conditions by promoting the infiltration and activation of inflammatory cells into injured or infected tissues and wound repair.

Some of CC chemokines including CCL3 and CCL5 (RANTES) are expressed in sepsis and exert proinflammatory effects by mediating organ specific leukocyte influx and activation. Members of the CXC chemokines are also implicated in the pathogenesis of systemic inflammatory response (36-39).

Asthma, the submucosa of small airways is infiltrated by mononuclear, eosinophil and mast cells causing mucous gland hyperplasia and subepithelial fibrosis. Asthmatic patients and animal models of allergic airway inflammation confirm a key role for chemokines in regulating lung inflammation. Chronic obstructive pulmonary disease (COPD) is characterized by progressive development of airflow limitation caused by chronic inflammation with increased recruitment of neutrophils, macrophages and IFN-γ-producing by CD8+ T cells in the lung, the levels of CXCL8 and CXCL10 are increased in COPD and it correlate with the degree of infiltration by neutrophils and CD8+ T cells (40).

Atherosclerosis is widely accepted as an inflammatory disease, that chemokines play a means role in leukocyte recruitment, angiogenesis, and more interestingly in the proliferation of vascular smooth muscle cells and their migration into plaques (41). Many factors known to promote atherosclerosis such as plasma cholesterol, hypertensión and diabetes, stimulate chemokine release by atheromatous lesions. Atherosclerotic lesions express a number of chemokines including CCL2, CCL3, CCL4, CCL5, CCL11 and CXCL8. The cellular sources of chemokines within atherosclerotic lesion are multiple and include support the involvement of CCL2/CCR2 chemokine receptor pair in atherosclerosis. CCL2 is essential for monocyte recruitment, has angiogenic activity and also causes smooth muscle cell proliferation and migration. Adhesion of leukocytes to endothelial cells also increases chemokine release in the pathogenic process of atherosclerosis. Therefore, chemokines and receptors become important molecular targets for avoiding the formation and development of atherosclerotic lesions (26, 42). This affords an excellent event of the importance of a functional chemokine receptor in contributing to the progression of atherosclerosis.

Rheumatoid arthritis (RA) is characterized by a mixed Th1-type inflammatory cell infiltration (Th1, neutrophils, monocytes) in synovial space of the joints, in association with cartilage destruction and bone remodeling. Chemokines produced in the inflamed joints attract leukocytes across the endothelial barrier to initiate and maintain active RA. Among CXC chemokines, high concentrations of CXCL8, CXCL5, and CXCL1 are detected in the sera, synovial fluids, and synovial tissues of RA patients. These chemokines attract neutrophils and promote angiogenesis. High production of CC chemokines CCL2, CCL3 and CCL5 which attract mainly monocytes is also found in RA (43, 44). CXCL12 expressed in the rheumatoid synovium, recruits CD4 memory T cells, which express increased levels of CXCR4, at the RA site. CXCL12 also blocks T cells from undergoing activation-induced apoptosis, thus further increasing the accumulation of T cells in the rheumatoid synovium. Interestingly, CXCL12 may induce the migration of DCs from blood stream into the rheumatoid area, implying its potential role in amplifying a detrimental autoimmune response. (45)

Multiple sclerosis (MS) as a chronic inflammatory demyelinating disorder of the central nervous system (CNS) is thought to be caused by an autoimmune response directed against self-myelin-associated antigens. The immune cells infiltrate in CNS lesions of MS patients consist of CD4, CD8 T cells and macrophages (46). Many chemokines are detected in active lesions in the CNS of MS patients and the cerebrospinal fluids of relapsing patients contain elevated levels of CCL3. In MS, infiltrating macrophages express CCR2 and CCR5, while T cells and reactive astrocytes in active lesions express CXCR3 and CCR5 (47-50). Similar chemokine expression patterns are found in experimental autoimmune encephalomyelitis (EAE), an animal model more related to MS. In EAE, increased expression of CCL2, CCL3, CCL4, CCL5 and CXCL10 correlates with the severity of the disease (78). Neutralizing antibodies to selected chemokines either inhibit the onset or reduce the severity of the EAE (51, 52). A more definitive correlation between chemokines and EAE was established by experiments with CCR1- and CCR2-deficient mice, in which a reduction in disease incidence and severity were clearly documented (53, 54).
Chemokines and Malignancy

Chemokine receptor expression profiles of cancer cells. Recent papers suggest that tumor cells may express restricted and specific patterns of chemokine receptors that responses to chemokine gradients may contribute to metastatic spread. There is one chemokine receptor that appears to be expressed by a majority of cancer types, namely CXCR4, which is expressed by 23 different types of cancer, including cancers of epithelial, mesenchymal and haematopoietic origin (55). For example, tumor cells from breast, prostate, pancreatic, lung and ovarian carcinomas, neuroblastoma and glioblastoma, all express CXCR4 (56-65). In other cancer cells studied, CXCR4 may be co-expressed with other CC or CXC chemokine receptors or less commonly, other receptors are present without expression of CXCR4. Human breast cancer cells express CXCR4 and CCR7 (59). Functional CCR7 is also found on gastric carcinoma cells (66) and esophageal carcinoma (67). Melanoma cells are reported to express CCR7 and CCR10 (59) and in another study to co-express CXCR4 and CXCR3 (68). Leukaemic and lymphoma cells express a wider range of chemokine receptors, probably reflecting their haematopoetic origin, adult T cell leukaemia/ lymphoma (ATLL) cells frequently express CXCR4 (69), cutaneous T cell lymphoma (CTCL) cells express functional CXCR3 (70) and B cell lymphomas are reported to express CXCR3 and CXCR5 (71).

Chemokines expression in the tumor microenvironment

Within most cancers there is an extensive network of chemokines and chemokine receptors (55, 72), often tumor production of chemokines is disregulated and receptor expression and signalling may be abnormal (73). Solid tumors comprise a mixture of malignant and host stromal cells. Initially, stromal cells have to be recruited into the tumor tissue by the cancer cells and although there are some reports of infiltrating immune cells controlling tumor growth (74), it is possibly more likely that a tumor attracts stromal cells which are advantageous for tumor growth. For example, infiltrating macrophages produce growth factors, angiogenic factors, inflammatory cytokines and chemokines (75). CCL2 stimulation of monocytes promoted tumor formation of melanoma cells (76). CD4+ T cells were reported to enhance invasion and tumor progression whereas benign breast disease had minimal chemokine expression (82). In an experimental murine breast cancer model, overexpression of the cytokine CSF-1 (M-CSF) increased infiltration of macrophages and accelerated tumor growth, invasion and metastasis (83). In esophageal squamous cell carcinomas CCL2 expression was significantly associated with the extent of macrophage infiltration, tumor cell invasion and tumor vascularity (84).

However, there are conflicting data on the association of CCL2 and CCL5 expression, the extent of the leukocyte infiltrate and tumor progression. For instance, high serum levels of CCL2 in pancreatic cancer patients correlated with the extent of macrophage infiltration into the tumor but was associated with good patient prognosis (85). It is clear that the tumor microenvironment contains an extensive and varied mix of chemokines, both CC and CXC chemokines and that this ‘network’ may control the leukocyte infiltrate into the tumor. In the following section we will discuss whether similar chemokine-receptor networks can control tumor cell movement out of a cancerous tissue.

SDF-1 (CXCL12) and human tumore pathogenesis

Expression and regulation of SDF-1 in tumor

Classically, two alternatively spliced isoforms of SDF have been identified. SDF-1α is an 89 amino acid protein that is the predominantly expressed form of SDF-1 while SDF-1β contains a four amino acid extension at the carboxyl terminus, CXCL12 was initially cloned from bone marrow stromal cells (86). Strikingly, CXCL12 is widely expressed in various organs including heart, liver, brain, kidney, skeletal muscle, and lymphoid organs. Vascular endothelial cells, stromal fibroblasts, and osteoblasts are the major cellular source for CXCL12 in these organs (87-91). Interestingly, high levels of functional CXCL12 were first reported in human ovarian cancer in 2001 (92-94). Subsequent studies documented a strong correlation between CXCL12 expression and bone marrow and lymph node metastasis of breast (95) and prostate cancer (96). Interest in the role of CXCL12/CXCR4 in tumor pathology was provoked by these studies. In addition to ovarian cancer, CXCL12 expression is reported in breast cancer (97), glioblastoma (98), pancreatic cancer (99),
prostate cancer (100), thyroid cancer (51), and many other human tumors. Tumor stroma is an active element of tumor microenvironment. Recently, it was shown that in breast cancer, activated stroma fibroblasts produce CXCL12 and contribute to tumor vascularization by endothelial stem cell attraction (101). It also has been suggested that CXCL12 is involved in prostate epithelial cell transformation induced by aging fibroblasts (102). Although CXCL12 does not directly induce transformation, CXCL12 may provide conditions supportive of a transforming event. Therefore, stroma and cancer cells, two main components of tumor microenvironment, can produce CXCL12. Strikingly, regulation of CXCL12 expression in the tumor microenvironment has been poorly studied. It has been reported that estradiol activates estrogen receptor and induces the production of CXCL12 by tumor cells (103). It observed that hypoxia triggers CXCL12 expression by primary human ovarian tumor cells (104) and prostate tumor cell lines.

**SDF-1 tumor proliferation and survival**

There is evidence to demonstrate that CXCL12 can modulate tumor cell proliferation and survival (105) provided the first evidence for mitotic CXCL12 activity in human tumors, CXCL12-dependent proliferation correlated with the activation of ERK1/2 and AKT pathways. Both these pathways are known to be involved with the transduction of proliferative signals in normal and tumor cells (106). CXCL12 can induce proliferation of several tumor cell lines, including ovarian carcinoma, small cell lung cancer, prostate cancer, neck squamous cell carcinoma, and pancreatic cancer. Mechanistically, CXCL12-dependent cell proliferation is linked to ERK activation (107, 108). CXCL12/CXCR4-mediated tumor cell proliferation may be regulated through estrogen signaling (109). About 60% of human ovarian and breast cancers are hormone dependent and over express the progesterone and/or estrogen receptors (110-111). It was demonstrated that CXCL12 was required for estrogen-induced proliferation of both breast and ovarian cancers. (109) CXCL12 also can regulate tumor cell apoptosis. CXCL12 activates NF-kB (Abroun S. submitted data). Moreover, activation of NF-kB can sensitize cancer cells to CXCL12 stimulation through upregulation of CXCR4 expression, which in turn inhibits radiation-induced tumor necrosis factor alpha (TNF-α) production and tumor apoptosis (112). Many chemotherapeutic drugs exert their effects by inducing apoptosis in the targeted cell population. CXCL12 can protect tumor cells from drug-induced apoptosis directly through the activation of antiapoptotic pathways but also indirectly by modulating the adherence of cancer cells. For example, CXCL12 mediates adhesion of small cell lung cancer cells (SCLC) to marrow stroma cells and protects SCLC against etoposide-induced apoptosis. The protective effect could be antagonized by CXCR4-specific inhibitors as well as by blocking integrin _4 (113-114). Similar observations are found in myeloma (115), glioma cells (116), and head and neck cancer (117). Thus CXCL12 signals may be implicated in tumor cell proliferation and survival.

**SDF-1 and tumor Vascularization**

CXCL12 exhibits angiogenic activity. Initially, the angiogenic role of CXCL12 was observed in mice lacking CXCL12 or CXCR4 (118, 119). These mice had defective formation of large vessels supplying the gastrointestinal tract. Subsequent in vitro studies suggested a potential effect of CXCL12 on blood vessel formation. For example, CXCL12 stimulates the formation of capillary-like structures with human vascular endothelial cells (120,121). Interestingly, although high concentrations of CXCL12 are able to induce angiogenesis in vivo (122), but, in presence of low concentrations of vascular endothelial growth factor (VEGF) (104), revealing profound synergistic effects between CXCL12 and VEGF. CXCL12 synergizes with soluble factors, including fibroblast growth factor (FGF) family members and VEGF (123), and coordinates with immune cells, including plasmacytoid DCs (124), to induce potent vascularization in vivo. Migration, expansion, and survival of vascular endothelial cells form the essential functional network of angiogenesis. Vascular endothelial cell migration is strongly dependent on CXCL12 (125, 126). In support of this, neutralizing antibodies against CXCL12 inhibit endothelial cell invasion into subcutaneously injected Matrigel (127). Hypoxia simultaneously stimulates CXCR4 expression (128, 129) and CXCL12 (104) production. Therefore, it is reasoned that hypoxia would promote vascular endothelial cell migration toward CXCL12 and induce tumor vascularization in a CXCL12-dependent manner.

**SDF-1 and tumor metastasis**

Tumor metastasis was once viewed as a passive consequence of a single tumor cell simply “escaping” from a primary tumor and traveling great distances through draining lymph nodes and blood, lodging in small blood vessels and thereby forming micrometastases (130). Recent data, however, have demonstrated that tumor metastasis is an active process employing multiple molecular and cellular mechanisms. The interaction between tumor cells and stroma is crucial for tumor metastasis (131-132).

**Multiple myeloma.**

Multiple myeloma (MM) is a monoclonal plasma cell anomaly and this is second hematopoietic malignancy in word. During B-cell differentiation into plasma cells, plasma cells undergo a coordinated change in chemokine responsiveness. As B cells differentiate into plasma cells, they become increasingly sensitive to CXCL12 while losing responsiveness to B- and T-zone chemokines (CXCL13, CCL19, CCL21) through respective down-regulation of CXCR5 and CCR7 (133-134). In addition to CXCR4, plasma cells express functional CXCR6,
CCR10, and CCR3 chemokine receptors. (135) recently was demonstrated a stage-specific homing of the earliest B-cell precursors (pre-pro-B cells) and plasma cells to the same marrow niches in which stromal cells secrete high levels of CXCL12, suggesting that CXCL12 maintains immature and terminally differentiated B-cell types in the marrow microenvironment. However, we founded that myeloma cell derived from MM patients express CXCR4 at different level as myeloma cell lines (Abroun S, unpublished data) but neither primary myeloma cell nor myeloma cell lines express SDF-1 (136). SDF-1 induced primary myeloma cells or myeloma cell lines proliferation in serum free condition by NF-KB and ERK pathways activation in-vitro. These result show the role of stromal cell in bone marrow to support myeloma cell survival and proliferation by SDF-1 secretion.(137).

Multiple myeloma cells home to the BM where they adhere to marrow stromal cells and extracellular matrix (ECM) proteins in the marrow microenvironment through VLA-4 integrins to stromal fibronectin. In addition, myeloma cells display functional CXCR4 chemokine receptors that cooperate with VLA-4 integrins in myeloma cell adhesion and migration..This mechanism may allow myeloma cells to home to the marrow microenvironment, where adhesive interactions promote growth, survival, and confer cell adhesion-mediated drug resistance (CAM-DR) (138).

**SDF-1 and tumor cell adhesion or migration**

Cancer dissemination can be viewed as a tissue remodeling process that involves proteolytic degradation of extracellular matrix. Metalloproteases (MMPs) are a family of enzymes involved in the degradation of extracellular matrix in the surrounding normal tissue and known to mediate cancer invasion and metastases (139). Activation of MMPs breaks down the physical barriers of metastasis, thus promoting invasion by cancer cells (140). Several studies have documented that CXCL12 induces MMP synthesis in different cell types (141) and facilitates tumor cell adhesion and colonization. CXCL12 also modulates the expression and function of cell surface integrin molecules and, in turn, promotes tumor cell adhesion. The CXCL12/CXCR4 pathway is involved in the “homing” of lymphocytes. It was hypothesized that chemokines and chemokine receptors including CXCL12/CXCR4 might mediate cancer cells to “home” to specific secondary sites, thereby promoting organ-specific metastasis. Blocking of CXCR4 expression on the cell surface greatly reduced the ability of colon cancer cells to metastasize to the liver and lungs (142). These studies demonstrate the pivotal role of CXCL12/CXCR4 in tumor metastasis.

Several papers published and shown human cancer cells including neuroblastoma (143), glioblastoma (98), ovarian (94), breast (3, 57), colon (54), pancreas (144), and prostate (100) express CXCL12. It is reasoned that endogenous CXCL12, together with CXCR4 on tumor cells, should keep cancer cells within the primary tumor environment, rather than facilitate metastasis over a long distance. Nonetheless, the effects of CXCL12/ CXCR4 on tumor metastasis may be explained by multiple factors in the tumor environment. In summary, although other factors need to be considered, it is evident that the CXCL12/CXCR4 pathway is implicated in the mechanistic process of tumor metastasis, including tumor cell adhesion and migration.

**CXCL12 and Therapeutic Applications**

Strong evidence demonstrates that CXCL12/CXCR4 signal is implicated in tumor proliferation, survival, vascularization, metastasis, and immunosuppression. The in vivo blockade of this pathway reduces tumor growth and metastasis in mouse models (142). Statistical studies suggest a possible negative association between high levels of CXCR4 expression and patient outcome in certain human tumors (97-144). Targeting CXCL12/CXCR4 pathway is a logic strategy in treating cancer patients. CXCR4 is one of the co-receptors for human immunodeficiency virus (HIV). AMD3100 is a CXCR4 antagonist and has been used in human clinical trials for treatment of HIV infection (145,146). AMD3100. Phase I pharmacokinetic studies demonstrated the feasibility of intravenous dosing and showed that AMD3100 was well tolerated by the healthy volunteers (47). Our results clarified that AMD3100 suppressed myeloma cell proliferation which stimulated by SDF-1 in-vitro, (abroun S. submitted data). AMD3100 also mobilized CD34 negative cells from the bone marrow into the peripheral blood of healthy volunteers as well as cancer patients (147,148). Although these studies did not test AMD3100 as an anti-cancer intervention, the observations suggest that CXCL12/CXCR4 inhibitors would be potentially used in clinical trials in treating cancer patients. On the other hand, thousands of patients worldwide have received treatment with angiogenesis inhibitors or antagonists. Bevacizumab, a monoclonal antibody against VEGF, is one of them (149). Although administration of bevacizumab results in increased patient survival with certain cancers (150,151), the clinical efficacy needs significant improvement. CXCL12 and VEGF synergistically induce tumor vascularization (104). Thus it is expected that combination of anti-VEGF and anti-CXCL12 may be more effective. It is possible that targeting CXCR4/ CXCL12 pathway may yield unexpected clinical effects. it is evident that CXCR4/CXCL12 pathway is actively implicated in tumor pathogenesis and plays a significant role in tumor immunopathogenesis. Therefore, manipulation of this pathway will establish new strategy for cancer treatment (151, 152). Thus it need to allow in mind that although targeting CXCR4/CXCL12 is an attractive option in treating human tumors, it is highly likely that to achieve effective, reliable, and consistent clinical efficacy, a complicated combinatorial therapeutic regimen may be warranted.
Conclusion

Chemokines are distinct from other cytokines in their structure, cell surface receptors and unique pattern of activities and they have been considering in physiological and pathophysiological conditions. Metastasis is a lethal yet entirely inefficient process, metastatic cells share many similarities with normal stem cells, including an unlimited capacity for self renewal; the requirement for a specific ‘niche’ or microenvironment to grow; use of the SDF-1/CXCR4 axis for migration; enhanced resistance to apoptosis; and an increased capacity for drug resistance. The experiments with gene depletion, using specific antibody neutralization and use siRNA suggest each chemokine and receptor may have a special position on the stage of orchestrated biological and pathophysiological responses. Chemokine research is a new field and the brief information contained in this review reflects only the tip of an iceberg whose full identity remains to be explored. It is predictable that the importance of chemokines and receptors will be further appreciated with the enthusiastic participation in the research by scientists from multi-disciplinary backgrounds and the development of new therapeutic agents directed against chemokines or receptors with proven effectiveness in circumventing human diseases.

References

34. Arenberg DA, Polverini PJ, Kunkel SL, et al. The role of
42. Quyyumi AA, Murphy PM. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res. 1998; 1: 401-407
71. Jones D, Benjamin RJ, Shahsafi A, Dormann F. The chemokine receptor CCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood. 2000; 95: 627-632
75. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet, 2001; 357: 539-545
76. Nesbit M, Schader H, Miller TH, Herlyn M. Low-level mono-
cyte chemotactic protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Im-
munol, 2001; 166: 6463-6490
77. Danel D, Meyer MN, Bergsland EK, Dehne K, Coussens LM, Hanahan D. Immune enhancement of skin carcinogenesis
78. Skinnider BF, Elia AJ, Gascogne RD, et al. Signal trans-
ducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.
Blood 2002; 99: 618-626
79. Negus RP, Stamp GW, Relief MG, et al. The detection and
83. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colonystimulat-
84. Ohta M, Kitadi Y, Tanaka S, et al. Monocyte chemotactant protein-1 expression correlates with macrophage infiltra-
86. Tashiro K, Tada H, Heilker R, Shirouzu M, Nakano T, Honjo T. Signal sequence trap: a cloning strategy for secreted pro-
cine receptors. Cell, 2006; 124: 175-189
88. Petit I, Szypier-Kravitz M, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regu-
89. Pett I, Szyper-Kravitz M, et al. VEGF-induced adult neurovascularization: recruitment, retention, and role of acces-
sory cells. Cell, 2006; 124: 175-189
90. Kryczek I, Lange A, Mottram P, et al. CXCL12 and vas-
cular endothelial growth factor synergistically induce neoangi-
91. Zou YR, Kottmann AH, Kuroda M, Tanisch U, Littman DR.
92. Kryczek I, Grybos M, Dlubek D, Klimczak A, Rabczynski J, Lange A. Accumulation of CD45RO_ cells in peritoneal carci-
mobilization by decreasing bone marrow SDF-1 and up-
93. Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR. Epithelial cancer cell migration: a role for chemokine recep-
tors? Cancer Res. 2001; 61: 4961-4965
95. Muller A, Homey B, Soto H, et al. Involvement of chemokine
96. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman
NS, McCauley LK. Use of the stromal cell-derived factor-1/
CXCR4 pathway in prostate cancer metastasis to bone. Can-
er Res. 2002; 62: 1832-1837
7: R402-R410
98. Rempel SA, Dudas S, Ge S, Gutierrez JA. Identification and localization of the cytokine SDF1 and its receptor, CXC
chemokine receptor 4, to regions of necrosis and angiogen-
sis in human glioblastoma. Clin Cancer Res2000; 6: 102-
111
99. Marchesi F, Monti P, Leone BE, et al. Increased survival,
proliferation, and migration in metastatic human pancreatic
64: 8420-8427
100. Sun YX, Wang J, Shelburne CE, et al. Expression of CX-
102. Begley L, Monteleone C, Shah RB, Macdonald JW, Ma-
coska JA. CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell. 2005; 4: 291-298-
103. Hall JM, Korach KS. Stromal cell-derived factor 1, a novel
role of estrogen receptor action, mediates the mitogenic and vas-
cular endothelial growth factor synergistically induce neoangio-
genesis in human ovarian cancers. Cancer Res 2005; 65:
1676-1686
104. Kryczek I, Lange A, Mottram P, et al. CXCL12 and vas-
cular endothelial growth factor synergistically induce neoangio-
genesis in human ovarian cancers. Cancer Res 2005; 65:
1676-1686
105. Sahgal A, Keener C, Boynton AL, Warrick J, Murphy GP,
CXCR4, a chemokine receptor, is overexpressed in and re-
quired for proliferation of glioblastoma tumor cells. J Surg Onc,
1998; 69: 99-104
1331-1339
107. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor-1/CXCL12-CXCR-
4 chemokine receptor 4, to regions of necrosis and angiogen-
the chemokine CXCL12 on epithelial tumor cells in human
110. Hall JM, Korach KS. Stromal cell-derived factor 1, a novel
role of estrogen receptor action, mediates the mitogenic ef-
fects of estradiol in ovarian and breast cancer cells. Mol Endo-
crinol, 2003; 17: 792-803
111. Jordan VC, Morrow M. Tamoxifen, raloxifene, and the
112. Wang CY, Mayo MW, Baldwin AS Jr. TNF and cancer
therapy: the story of a program. Science, 1996; 274: 784-787
113. Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M.
CXCR4 chemokine receptor and integrin signaling co-operate

in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene, 2005; 24: 4462-4471


120. Molino M, Woolkalis MJ, Prevost N, et al. CXCR4 on human endothelial cells can serve as both a mediator of biological responses and as a receptor for HIV-2. Biochim Biophys Acta. 2000; 1500: 227-240


124. Cyster JG. Homing of antibody secreting cells. Immuno Rev. 2003; 194: 48-60


134. Cyster JG. Homing of antibody secreting cells. Immuno Rev. 2003; 194: 48-60


